Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma

Cancer Research

Volumn 69, Issue 2, 2009, Pages 526-536

  Lamoureux, Francois ^a,b,f   Picarda, Gaëlle ^a,b   Garrigue Antar, Laure ^b,c   Baud'huin, Marc ^a,b   Trichet, Valerie ^a,b   Vidal, André ^f   Miot Noirault, Elisabeth ^f   Pitard, Bruno ^d   Heymann, Dominique ^a,b,e   Rédini, Françoise ^a,b  

^a Institut National de la Sante et de la Recherche Medicale ERI 7   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Team 12   (France)

^d IN CELL ART   (France)

^e HÔTEL DIEU   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARIN BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OSTEOPROTEGERIN[1-194]; OSTEOPROTEGERIN[1-401]; PLASMID DNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; SURVIVAL RATE; TRANSGENE; TUMOR GROWTH; TUMOR VOLUME;

EID: 58349111534     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2648     Document Type: Article

References (43)

1. Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 2007;7:169-81.
2. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007;2:6.
3. Guise TA. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2002;2:570-2.
4. Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003;163:2021-31.
5. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 2005;10:197-204.
6. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57.
7. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
8. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97:887-92.
9. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
10. Lamoureux F, Richard P,Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007;67:7308-18.
11. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci Lond 2006;110:279-91.
12. Fisher JL, Thomas-Mudge RJ, Elliott J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006;66:3620-8.
13. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
14. Nyambo R, Cross N, Lippitt J, et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 2004;19:1712-21.
15. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004;86:269-79.
16. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6.
17. Lamoureux F, Baud'huin M, Duplomb L, Heymann D, Redini F. Proteoglycans: key partners in bone cell biology. Bioessays 2007;29:758-71.
18. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006;5:2139-48.
19. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100:3002-7.
20. Mosheimer BA, Kaneider NC, Feistritzer C, et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 2005;90:2964-71.
21. Theoleyre S, Kwan Tat S, Vusio P, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor nB ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006;347:460-7.
22. Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett 2002;188:213-9.
23. Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 2006;28:261-9.
24. Richard P, Bossard F, Desigaux L, Lanctin C, Bello-Roufai M, Pitard B. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther 2005;16:1318-24.
25. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
26. 99mTc]polyazamacrocycles, potential radiotracers for cartilage imaging. J Labelled Cpd Radiopharm 2000;43:585-94.
27. Corey E, Brown LG, Kiefer JA, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005;65:1710-8.
28. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25:119-29.
29. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
30. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117-23.
31. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-nB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007;282:31601-9.
32. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62:1619-23.
33. Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R. Disabling of receptor activator of nuclear factor-κB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem 2004;279:8269-77.
34. Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 2007;67:202-8.
35. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-40.
36. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-9.
37. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
38. Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000;275:23319-25.
39. Shin J, Kim YM, Li SZ, Lim SK, Lee W. Structure-function of the TNF receptor-like cysteine-rich domain of osteoprotegerin. Mol Cells 2008;25:352-7.
40. Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007;41:165-74.
41. Shinmyouzu K, Takahashi T, Ariyoshi W, Ichimiya H, Kanzaki S, Nishihara T. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand. Biochem Biophys Res Commun 2007;354:447-52.
42. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 2000;96:2528-36.
43. Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-κB ligand. J Biol Chem 2005;280:41155-64.